GlassScriptPhysician profile
Pauline Lau
NPI 1972576114
$51,244.39
in general payments reported to CMS, 2019-2025
57 companies · $3,913 in 2025
The $3,913 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $8,781 · 2021: $6,345 · 2022: $4,958 · 2023: $6,296 · 2024: $4,417 · 2025: $3,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,790 · Food and Beverage: $6,100 · Education: $377 · Honoraria: $350 · Travel and Lodging: $8.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,790.00 |
| Food and Beverage | $6,099.94 |
| Education | $377.24 |
| Honoraria | $350.00 |
| Travel and Lodging | $8.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,483.56 | 2019-2025 | Tagrisso, Imfinzi, Farxiga |
| Janssen Biotech, INC. | $4,091.75 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $3,111.96 | 2019-2025 | |
| Genentech USA, INC. | $2,862.78 | 2019-2023 | Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $2,593.24 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,546.98 | 2019-2025 | |
| Pfizer INC. | $2,328.95 | 2019-2025 | |
| Taiho Oncology, INC. | $1,795.67 | 2019-2025 | |
| Incyte Corporation | $1,694.30 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $1,398.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,076.12 | 2019-2025 | |
| Lilly USA, LLC | $1,036.23 | 2019-2025 | Verzenio, Jaypirca, Kisunla |
| Glaxosmithkline, LLC. | $855.83 | 2020-2025 | Shingrix, Ojjaara, Zejula |
| Abbvie INC. | $854.20 | 2019-2025 | |
| Astellas Pharma US INC | $816.08 | 2019-2024 | Xtandi, Padcev |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $647.74 | 2019-2024 | Reblozyl, Pomalyst |
| Puma Biotechnology, INC. | $433.03 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $413.92 | 2019-2023 | Keytruda |
| Amgen INC. | $404.60 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| Array Biopharma INC | $330.72 | 2020-2024 | Braftovi, Mektovi, Xalkori |
| Takeda Pharmaceuticals U.S.A., INC. | $296.56 | 2019-2022 | |
| Ge Healthcare | $241.40 | 2022 | |
| Sumitomo Pharma America, INC. | $239.78 | 2023-2025 | Orgovyx |
| Medtronic, INC. | $200.14 | 2022 | |
| Daiichi Sankyo INC. | $189.93 | 2021-2025 | Enhertu, Datroway |
| Mirati Therapeutics, INC. | $162.67 | 2023-2024 | Krazati |
| Myovant Sciences INC. | $157.52 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $152.54 | 2019 | |
| Genzyme Corporation | $146.24 | 2022 | |
| Kite Pharma, INC. | $145.49 | 2020-2023 | |
| Gilead Sciences, INC. | $142.50 | 2019-2025 | Trodelvy |
| Exelixis INC. | $136.85 | 2019-2025 | Cabometyx |
| Seagen INC. | $127.99 | 2020-2023 | Tukysa |
| Shield Therapeutics INC | $126.20 | 2024-2025 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Shionogi INC | $125.00 | 2019 | |
| Emd Serono, INC. | $115.08 | 2019-2024 | Tepmetko |
| Janssen Pharmaceuticals, INC | $111.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $106.01 | 2020-2021 | |
| Dova Pharmaceuticals | $80.31 | 2020-2021 | |
| Tesaro, INC. | $80.13 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $79.75 | 2020-2022 | |
| Foundation Medicine, INC. | $69.28 | 2019-2021 | |
| Epizyme, INC. | $64.22 | 2020-2022 | |
| Agios Pharmaceuticals, INC. | $55.30 | 2025 | Pyrukynd |
| Verastem, INC. | $55.22 | 2019-2020 | |
| Genentech, INC. | $49.95 | 2021 | |
| G1 Therapeutics, INC. | $46.12 | 2022 | |
| Coherus Oncology, INC. | $25.49 | 2024 | |
| Sobi, INC | $22.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.46 | 2020 | |
| Rigel Pharmaceuticals, INC. | $19.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.42 | 2020 | |
| Clovis Oncology, INC. | $17.13 | 2019 | |
| Karyopharm Therapeutics INC. | $16.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.